"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.31 which represents a slight increase of $0.15 or 6.94% from the prior close of $2.16. The stock opened at $2.3 and ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Brain drug developer Alector is ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in a string of investigational meds missing the mark in the indication ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...

Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...

Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.

Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.